{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:43:32Z","timestamp":1791218612498,"version":"4.1.0"},"reference-count":56,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2861,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["SFB575"],"award-info":[{"award-number":["SFB575"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Wilhelm-Sander-Stiftung"},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,11]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      <jats:bold>Tumor necrosis factor\u2013related apoptosis-inducing ligand (TRAIL) induces apoptosis in tumor cells but not in most normal cells and has therefore been proposed as a promising antitumor agent. Recent experiments suggested that isolated primary human hepatocytes but not monkey liver cells are susceptible to certain TRAIL agonists, raising concerns about the use of TRAIL in cancer treatment. Whether TRAIL indeed exerts hepatotoxicity<\/jats:bold>\n                      <jats:bold>in vivo<\/jats:bold>\n                      <jats:bold>and how this is influenced by chemotherapeutic drugs or liver disease are completely unknown. Employing different forms of recombinant TRAIL, we found that the cytokine can induce proapoptotic caspase activity in isolated human hepatocytes. However in marked contrast, these different TRAIL preparations induced little or no cytotoxicity when incubated with tissue explants of fresh healthy liver, an experimental model that may more faithfully mimic the<\/jats:bold>\n                      <jats:bold>in vivo<\/jats:bold>\n                      <jats:bold>situation. In healthy liver, TRAIL induced apoptosis only when combined with histone deacetylase inhibitors. Strikingly, however, TRAIL alone triggered massive apoptosis accompanied by caspase activation in tissue explants from patients with liver steatosis or hepatitis C viral infection. This enhanced sensitivity of diseased liver was associated with an increased expression of TRAIL receptors and up-regulation of proapoptotic Bcl-2 proteins.<\/jats:bold>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>\n                      <jats:bold>These results suggest that clinical trials should be performed with great caution when TRAIL is combined with chemotherapy or administered to patients with inflammatory liver diseases.<\/jats:bold>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hep.21846","type":"journal-article","created":{"date-parts":[[2007,8,17]],"date-time":"2007-08-17T16:16:28Z","timestamp":1187367388000},"page":"1498-1508","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":127,"title":["Increased hepatotoxicity of tumor necrosis factor\u2013related apoptosis-inducing ligand in diseased human liver"],"prefix":"10.1097","volume":"46","author":[{"given":"Xandra","family":"Volkmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias J.","family":"Bahr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Lehner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"MacFarlane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald M.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Manns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Schulze-Osthoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Bantel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-24-20241201","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/sj.cdd.4401187","article-title":"Apo2LTRAIL and its death and decoy receptors.","volume":"10","author":"LeBlanc","year":"2003","journal-title":"Cell Death Differ"},{"key":"R2-24-20241201","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/35008667","article-title":"TRAIL receptor2 signals apoptosis through FADD and caspase8.","volume":"2","author":"Bodmer","year":"2000","journal-title":"Nat Cell Biol"},{"key":"R3-24-20241201","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S1074-7613(00)80212-5","article-title":"Apo2LTRAILdependent recruitment of endogenous FADD and caspase8 to death receptors 4 and 5.","volume":"12","author":"Kischkel","year":"2000","journal-title":"Immunity"},{"key":"R4-24-20241201","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1093\/emboj\/cdf441","article-title":"Caspase10 is recruited to and activated at the native TRAIL and CD95 deathinducing signalling complexes in a FADDdependent manner but can not functionally substitute caspase8.","volume":"21","author":"Sprick","year":"2002","journal-title":"EMBO J"},{"key":"R5-24-20241201","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.immuni.2004.11.008","article-title":"TRAILR as a negative regulator of innate immune cell responses.","volume":"21","author":"Diehl","year":"2004","journal-title":"Immunity"},{"key":"R6-24-20241201","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1084\/jem.189.8.1343","article-title":"Monocytemediated tumoricidal activity via the tumor necrosis factorrelated cytokine, TRAIL.","volume":"189","author":"Griffith","year":"1999","journal-title":"J Exp Med"},{"key":"R7-24-20241201","doi-asserted-by":"crossref","first-page":"920","DOI":"10.4049\/jimmunol.163.2.920","article-title":"IFNgamma mediates a novel antiviral activity through dynamic modulation of TRAIL and TRAIL receptor expression.","volume":"163","author":"Sedger","year":"1999","journal-title":"J Immunol"},{"key":"R8-24-20241201","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1074-7613(02)00502-2","article-title":"Natures TRAILon a path to cancer immunotherapy.","volume":"18","author":"Smyth","year":"2003","journal-title":"Immunity"},{"key":"R9-24-20241201","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1054\/drup.2001.0208","article-title":"Potential and caveats of TRAIL in cancer therapy.","volume":"4","author":"Held","year":"2001","journal-title":"Drug Resist Updat"},{"key":"R10-24-20241201","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/sj.cdd.4401649","article-title":"Chronic lymphatic leukemic cells exhibit apoptotic signaling via TRAILR1.","volume":"12","author":"MacFarlane","year":"2005","journal-title":"Cell Death Differ"},{"key":"R11-24-20241201","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/nm1161","article-title":"Tumorselective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells.","volume":"11","author":"Nebbioso","year":"2005","journal-title":"Nat Med"},{"key":"R12-24-20241201","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nm1160","article-title":"Insinga, A, Monestiroli, S, Ronzoni S, Gelmetti V, Marchesi F, Viale A, et al. Inhibitors of histone deacetylases induce tumorselective apoptosis through activation of the death receptor pathway.","volume":"11","year":"2005","journal-title":"Nat Med"},{"key":"R13-24-20241201","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/hep.21054","article-title":"HDAC inhibitor treatment of hepatoma cells induces both TRAILindependent apoptosis and restoration of sensitivity to TRAIL.","volume":"43","author":"Pathil","year":"2006","journal-title":"Hepatology"},{"key":"R14-24-20241201","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1038\/sj.cdd.4401535","article-title":"Histone deacetylase inhibitors potentiate TNFrelated apoptosisinducing ligand (TRAIL)induced apoptosis in lymphoid malignancies.","volume":"11","author":"Inoue","year":"2004","journal-title":"Cell Death Differ"},{"key":"R15-24-20241201","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1158\/0008-5472.CAN-05-4563","article-title":"Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factorrelated apoptosisinducing ligandinduced apoptosis.","volume":"66","author":"Inoue","year":"2006","journal-title":"Cancer Res"},{"key":"R16-24-20241201","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/5517","article-title":"Tumoricidal activity of tumor necrosis factorrelated apoptosisinducing ligand in vivo.","volume":"5","author":"Walczak","year":"1999","journal-title":"Nat Med"},{"key":"R17-24-20241201","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1172\/JCI6926","article-title":"Safety and antitumor activity of recombinant soluble Apo2 ligand.","volume":"104","author":"Ashkenazi","year":"1999","journal-title":"J Clin Invest"},{"key":"R18-24-20241201","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/75045","article-title":"Apoptosis induced in normal human hepatocytes by tumor necrosis factorrelated apoptosisinducing ligand.","volume":"6","author":"Jo","year":"2000","journal-title":"Nat Med"},{"key":"R19-24-20241201","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S0140-6736(00)02659-3","article-title":"Human braincell death induced by tumournecrosisfactorrelated apoptosisinducing ligand (TRAIL).","volume":"356","author":"Nitsch","year":"2000","journal-title":"Lancet"},{"key":"R20-24-20241201","first-page":"553","article-title":"Regulation of tumor necrosis factorrelated apoptosisinducing ligand sensitivity in primary and transformed human keratinocytes.","volume":"60","author":"Leverkus","year":"2000","journal-title":"Cancer Res"},{"key":"R21-24-20241201","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/86397","article-title":"Differential hepatocyte toxicity of recombinant Apo2LTRAIL versions.","volume":"7","author":"Lawrence","year":"2001","journal-title":"Nat Med"},{"key":"R22-24-20241201","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1158\/1078-0432.CCR-05-2635","article-title":"Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs.","volume":"12","author":"Ganten","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R23-24-20241201","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/jhep.2001.25173a","article-title":"Is TRAIL hepatotoxic?","volume":"34","author":"Gores","year":"2001","journal-title":"Hepatology"},{"key":"RU24-24-20241201","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/0168-8278(95)80226-6","article-title":"Histological grading and staging of chronic hepatitis.","volume":"22","author":"Ishak","year":"1995","journal-title":"J Hepatol"},{"key":"RU25-24-20241201","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1056-8719(01)00127-7","article-title":"The applicability of rat and human liver slices to the study of mechanisms of hepatic drug uptake.","volume":"45","author":"Olinga","year":"2001","journal-title":"J Pharmacol Toxicol Methods"},{"key":"RU26-24-20241201","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0300-483X(00)00316-4","article-title":"Precisioncut liver slices: characteristics and use for in vitro pharmacotoxicology.","volume":"153","author":"LercheLangrand","year":"2000","journal-title":"Toxicology"},{"key":"RU27-24-20241201","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1096\/fasebj.3.2.2914628","article-title":"Hepatocyte function and extracellular matrix geometry: longterm culture in a sandwich configuration.","volume":"3","author":"Dunn","year":"1989","journal-title":"FASEB J"},{"key":"R28-24-20241201","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1021\/bi992242l","article-title":"A unique zincbinding site revealed by a highresolution Xray structure of homotrimeric Apo2LTRAIL.","volume":"39","author":"Hymowitz","year":"2000","journal-title":"Biochemistry"},{"key":"R29-24-20241201","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1002\/hep.21186","article-title":"Caspase activation is required for antiviral treatment response in chronic hepatitis C virus infection.","volume":"43","author":"Volkmann","year":"2006","journal-title":"Hepatology"},{"key":"R30-24-20241201","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/hep.20747","article-title":"The extent of liver steatosis in chronic hepatitis C virus infection is mirrored by caspase activity in serum.","volume":"42","author":"Seidel","year":"2005","journal-title":"Hepatology"},{"key":"R31-24-20241201","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0022-3565(24)29298-3","article-title":"Preclinical studies to predict the disposition of Apo2Ltumor necrosis factorrelated apoptosisinducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety.","volume":"299","author":"Kelly","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"R32-24-20241201","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1124\/dmd.104.000323","article-title":"Tissue distribution, stability, and pharmacokinetics of APO2 ligandtumor necrosis factorrelated apoptosisinducing ligand in human colon carcinoma COLO205 tumorbearing nude mice.","volume":"32","author":"Xiang","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"R33-24-20241201","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2174\/138920006778017759","article-title":"Molecular mechanisms underlying the dedifferentiation process of isolated hepatocytes and their cultures.","volume":"7","author":"Elaut","year":"2006","journal-title":"Curr Drug Metab"},{"key":"R34-24-20241201","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1023\/A:1007402505482","article-title":"Isolated hepatocytespast, present and future.","volume":"13","author":"Berry","year":"1997","journal-title":"Cell Biol Toxicol"},{"key":"R35-24-20241201","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1081\/DMR-120023684","article-title":"New hepatocyte in vitro systems for drug metabolism: metabolic capacity and recommendations for application in basic research and drug development, standard operation procedures.","volume":"35","author":"Gebhardt","year":"2003","journal-title":"Drug Metab Rev"},{"key":"R36-24-20241201","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1158\/1078-0432.CCR-05-2689","article-title":"Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors.","volume":"12","author":"Shah","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R37-24-20241201","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S0168-8278(02)00209-X","article-title":"Death receptormediated apoptosis and the liver.","volume":"37","author":"Yoon","year":"2002","journal-title":"J Hepatol"},{"key":"R38-24-20241201","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/hep.20411","article-title":"Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury.","volume":"40","author":"Bantel","year":"2004","journal-title":"Hepatology"},{"key":"R39-24-20241201","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors.","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"R40-24-20241201","first-page":"6259","article-title":"The caspase 9 inhibitor ZLEHDFMK protects human liver cells while permitting death of cancer cells exposed to tumor necrosis factorrelated apoptosisinducing ligand.","volume":"60","author":"Ozoren","year":"2000","journal-title":"Cancer Res"},{"key":"R41-24-20241201","first-page":"3620","article-title":"Targeted expression of green fluorescent proteintumor necrosis factorrelated apoptosisinducing ligand fusion protein from human telomerase reverse transcriptase promoter elicits antitumor activity without toxic effects on primary human hepatocytes.","volume":"62","author":"Lin","year":"2002","journal-title":"Cancer Res"},{"key":"R42-24-20241201","first-page":"2369","article-title":"Adenoviral gene transfer of tumor necrosis factorrelated apoptosisinducing ligand overcomes an impaired response of hepatoma cells but causes severe apoptosis in primary human hepatocytes.","volume":"63","author":"Armeanu","year":"2003","journal-title":"Cancer Res"},{"key":"R43-24-20241201","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/sj.cdd.4401331","article-title":"Human normal hepatocytes are susceptible to apoptosis signal mediated by both TRAILR1 and TRAILR2.","volume":"11","author":"Mori","year":"2004","journal-title":"Cell Death Differ"},{"key":"RU44-24-20241201","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/sj.onc.1205151","article-title":"Tumor necrosis factorrelated apoptosisinducing ligand (TRAIL) triggers apoptosis in normal prostate epithelial cells.","volume":"21","author":"Nesterov","year":"2002","journal-title":"Oncogene"},{"key":"RU45-24-20241201","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/sj.cdd.4400965","article-title":"Inflammatory cytokine regulation of TRAILmediated apoptosis in thyroid epithelial cells.","volume":"9","author":"Bretz","year":"2002","journal-title":"Cell Death Differ"},{"key":"RU46-24-20241201","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.4049\/jimmunol.171.3.1526","article-title":"TRAIL induces apoptosis and inflammatory gene expression in human endothelial cells.","volume":"171","author":"Li","year":"2003","journal-title":"J Immunol"},{"key":"R47-24-20241201","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0070-2153(05)72004-4","article-title":"Regulation of hepatocyte cell cycle progression and differentiation by type I collagen structure.","volume":"72","author":"Hansen","year":"2006","journal-title":"Curr Top Dev Biol"},{"key":"R48-24-20241201","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/hep.21223","article-title":"In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease.","volume":"44","author":"Wieckowska","year":"2006","journal-title":"Hepatology"},{"key":"R49-24-20241201","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1136\/gut.2004.056929","article-title":"Tumour necrosis factor related apoptosis inducing ligand (TRAIL) induces hepatic steatosis in viral hepatitis and after alcohol intake.","volume":"54","author":"Mundt","year":"2005","journal-title":"Gut"},{"key":"R50-24-20241201","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1172\/JCI200419255","article-title":"Critical roles of TRAIL in hepatic cell death and hepatic inflammation.","volume":"113","author":"Zheng","year":"2004","journal-title":"J Clin Invest"},{"key":"R51-24-20241201","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1172\/JCI27726","article-title":"TRAIL receptormediated JNK activation and Bim phosphorylation critically regulate Fasmediated liver damage and lethality.","volume":"116","author":"Corazza","year":"2006","journal-title":"J Clin Invest"},{"key":"R52-24-20241201","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1055\/s-2007-1007147","article-title":"Dysregulation of apoptosis as a mechanism of liver disease: an overview.","volume":"18","author":"Patel","year":"1998","journal-title":"Semin Liver Dis"},{"key":"R53-24-20241201","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1053\/he.2000.7123","article-title":"Liver cell apoptosis in chronic hepatitis C correlates with histological but not biochemical activity or serum HCVRNA levels.","volume":"31","author":"Calabrese","year":"2000","journal-title":"Hepatology"},{"key":"R54-24-20241201","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1053\/jhep.2001.28229","article-title":"Caspase activation correlates with the degree of inflammatory liver injury in chronic hepatitis C virus infection.","volume":"34","author":"Bantel","year":"2001","journal-title":"Hepatology"},{"key":"R55-24-20241201","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1038\/sj.cdd.4401119","article-title":"Apoptosis in hepatitis C virus infection.","volume":"10","author":"Bantel","year":"2003","journal-title":"Cell Death Differ"},{"key":"R56-24-20241201","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1136\/gut.2006.118059","article-title":"Free fatty acids sensitize hepatocytes to trial medicated cytotoxicity.","volume":"56","author":"Malhi","year":"2007","journal-title":"Gut"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.21846","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-200711000-00024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T07:39:39Z","timestamp":1737358779000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-200711000-00024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11]]},"references-count":56,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.21846","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2007,11]]}}}